Patient and treatment characteristics
| Characteristic . | FL* . | tFL† . | All patients . |
|---|---|---|---|
| No. of patients | 8 | 13 | 21 |
| Age | |||
| Median (interquartile range), y | 53 (49-57) | 60 (52-64) | 56 (51-62) |
| ≥65 y, n (%) | 1 (13) | 2 (15) | 3 (14) |
| Male sex, n (%) | 5 (63) | 9 (69) | 14 (67) |
| ECOG performance-status score ≥1, n (%) | 3 (38) | 5 (38) | 8 (38) |
| LDH, prelymphodepletion > ULN, n (%) | 1 (13) | 9 (69) | 10 (48) |
| Disease stage, n (%)‡ | |||
| I or II | 2 (25) | 0 | 2 (10) |
| III or IV | 6 (75) | 13 (100) | 19 (90) |
| Extranodal disease, n (%) | |||
| Yes | 5 (62) | 12 (92) | 17 (81) |
| No | 3 (38) | 1 (8) | 4 (19) |
| FLIPI score, n (%)§ | |||
| 0-1 | 2 (25) | 1 (8) | 3 (14) |
| 2 | 2 (25) | 2 (15) | 4 (19) |
| ≥3 | 4 (50) | 10 (77) | 14 (67) |
| Bulky disease|| | |||
| Yes | 2 (25) | 6 (46) | 8 (38) |
| No | 6 (75) | 7 (54) | 13 (62) |
| Bone marrow involvement | |||
| Yes | 4 (50) | 2 (15) | 6 (29) |
| No | 4 (50) | 11 (85) | 15 (71) |
| Tumor cross-sectional area¶ | |||
| Median, mm2 | 2995 | 4695 | 3343 |
| Interquartile range, mm2 | 2079-4208 | 2849-7265 | 2555-5794 |
| Prior therapies | |||
| Median (range) | 4 (2-7) | 5 (2-8) | 5 (2-8) |
| ≥4 prior lines of therapy, n (%) | 7 (88) | 11 (85) | 18 (86) |
| Prior autologous HCT, n (%) | |||
| Yes | 3 (38) | 7 (54) | 10 (48) |
| No | 5 (62) | 6 (46) | 11 (52) |
| Prior allogeneic HCT, n (%) | |||
| Yes | 1 (12) | 2 (15) | 3 (14) |
| No | 7 (88) | 11 (85) | 18 (86) |
| Bridging therapy between leukapheresis and lymphodepletion# | |||
| Yes | 1 (12) | 4 (31) | 5 (24) |
| No | 7 (88) | 9 (69) | 16 (76) |
| Lymphodepletion regimen, n (%) | |||
| Cy 60 mg/kg × 1 + Flu 25 mg/m2 × 3 | 5 (62) | 6 (46) | 11 (52) |
| Cy 30 mg/kg × 1 + Flu 25 mg/m2 × 3 | 0 | 3 (23) | 3 (14) |
| Cy 300 mg/m2 × 3 + Flu 30 mg/m2 × 3 | 3 (38) | 4 (31) | 7 (34) |
| Characteristic . | FL* . | tFL† . | All patients . |
|---|---|---|---|
| No. of patients | 8 | 13 | 21 |
| Age | |||
| Median (interquartile range), y | 53 (49-57) | 60 (52-64) | 56 (51-62) |
| ≥65 y, n (%) | 1 (13) | 2 (15) | 3 (14) |
| Male sex, n (%) | 5 (63) | 9 (69) | 14 (67) |
| ECOG performance-status score ≥1, n (%) | 3 (38) | 5 (38) | 8 (38) |
| LDH, prelymphodepletion > ULN, n (%) | 1 (13) | 9 (69) | 10 (48) |
| Disease stage, n (%)‡ | |||
| I or II | 2 (25) | 0 | 2 (10) |
| III or IV | 6 (75) | 13 (100) | 19 (90) |
| Extranodal disease, n (%) | |||
| Yes | 5 (62) | 12 (92) | 17 (81) |
| No | 3 (38) | 1 (8) | 4 (19) |
| FLIPI score, n (%)§ | |||
| 0-1 | 2 (25) | 1 (8) | 3 (14) |
| 2 | 2 (25) | 2 (15) | 4 (19) |
| ≥3 | 4 (50) | 10 (77) | 14 (67) |
| Bulky disease|| | |||
| Yes | 2 (25) | 6 (46) | 8 (38) |
| No | 6 (75) | 7 (54) | 13 (62) |
| Bone marrow involvement | |||
| Yes | 4 (50) | 2 (15) | 6 (29) |
| No | 4 (50) | 11 (85) | 15 (71) |
| Tumor cross-sectional area¶ | |||
| Median, mm2 | 2995 | 4695 | 3343 |
| Interquartile range, mm2 | 2079-4208 | 2849-7265 | 2555-5794 |
| Prior therapies | |||
| Median (range) | 4 (2-7) | 5 (2-8) | 5 (2-8) |
| ≥4 prior lines of therapy, n (%) | 7 (88) | 11 (85) | 18 (86) |
| Prior autologous HCT, n (%) | |||
| Yes | 3 (38) | 7 (54) | 10 (48) |
| No | 5 (62) | 6 (46) | 11 (52) |
| Prior allogeneic HCT, n (%) | |||
| Yes | 1 (12) | 2 (15) | 3 (14) |
| No | 7 (88) | 11 (85) | 18 (86) |
| Bridging therapy between leukapheresis and lymphodepletion# | |||
| Yes | 1 (12) | 4 (31) | 5 (24) |
| No | 7 (88) | 9 (69) | 16 (76) |
| Lymphodepletion regimen, n (%) | |||
| Cy 60 mg/kg × 1 + Flu 25 mg/m2 × 3 | 5 (62) | 6 (46) | 11 (52) |
| Cy 30 mg/kg × 1 + Flu 25 mg/m2 × 3 | 0 | 3 (23) | 3 (14) |
| Cy 300 mg/m2 × 3 + Flu 30 mg/m2 × 3 | 3 (38) | 4 (31) | 7 (34) |
Cy, cyclophosphamide; ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; Flu, fludarabine; LDH, lactate dehydrogenase; tFL, diffuse large B-cell lymphoma transformed from follicular lymphoma; ULN, upper limit of normal.
Three patients with grade 3A FL, and 3 patients with grade 1 to 2 FL; grading not available for 2 patients.
Four patients with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; MYC rearrangement not available for 4 patients.
Ann Arbor stage.
FLIPI scores include low risk (0 or 1 factor), intermediate risk (2 factors), and high risk (≥3 factors).
A tumor lesion with a greatest diameter ≥7 cm or ≥3 nodes with a greatest diameter at each site ≥3 cm.25
Sum of the product of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites.13
Chemotherapy (eg, bendamustine + rituximab) or >1 dose of dexamethasone 20 mg or equivalent not as part of chemotherapy regimen.